Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
May 14, 2020
Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO
Mar 03, 2020
BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Feb 06, 2020
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
Dec 19, 2019
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
Nov 11, 2019
Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting
Sep 21, 2019
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab
Aug 08, 2019
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Apr 02, 2019
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
Mar 28, 2019
Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
Mar 07, 2019
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
Dec 11, 2018
Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015
Nov 14, 2018
Tikcro Technologies Reports Third Quarter 2018 Results
Oct 20, 2018
Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
Oct 18, 2018
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CTLA-4 Monoclonal Antibody
Oct 10, 2018
Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial
Oct 04, 2018
BioAtla Congratulates James Allison, Ph.D. For Receiving Nobel Prize
Aug 27, 2018
CStone's Anti-CTLA-4 Antibody CS1002 Receives IND Approval in China
Jul 16, 2018
Agenus Appoints Regulatory and Clinical Heads
Jul 09, 2018
ImaginAb Appoints James Allison, Padmanee Sharma and Ramy Ibrahim to Scientific Advisory Board